TB Vaccine Pipeline
Which candidates are in trials, what stage they are in, and when results are expected.
Developed in honor of World TB Day 2026, this zine demystifies vaccines, TB, and leading TB vaccine candidates. Tapping into optimism for a future TB vaccine and the importance of community care through vaccination, this zine grounds the conversation in what an effective new TB vaccine would look like for communities, how vaccines integrate into the larger TB prevention strategy, and how a new TB vaccine for adults and adolescents could be a powerful tool in the quest to end TB.
Vaccine clinical trials have different inputs and outputs at each phase of the clinical pathway. This guide explores what researchers are looking for at each trial phase and how big each trial is. In this cheat sheet, vaccine trials are compared to the diagnostic and treatment trial requirements to highlight how clinical trials and timelines differ across innovations.
This cheat sheet designed specifically for community activists gives readers a high level overview of the basic science behind different common vaccine types (i.e., mRNA vaccines, viral vector vaccines). The vaccine types included all represent types of vaccines under development for the TB and the cheat sheet provides examples of well known vaccines for other diseases that use a similar design model. The cheats sheet notes key considerations that influence the efficacy, safety, acceptance, and accessibility of vaccines.
Over one hundred years after the introduction of BCG, the TB Vaccine Pipeline holds the potential for a new TB vaccine. This crash course covers the history, immunology and science behind the development of TB vaccines, and covers the major developments that lead to the opening of recent phase III trials.
The Working Group on New TB Vaccines TB Vaccine Pipeline covers TB vaccine candidates from preclinical proof-of-concept models to post-marketing studies. Candidates for each category can be viewed by latest stage of development, or on a sortable page that filters candidates by certain categories. Follow the pipeline as candidates move along the development pathway towards the goal of entering Phase III trials.
The long awaited results from the PreVenTB trial of two candidate TB vaccines — VPM1002 and Immuvac — were disappointing for the vaccine candidates themselves, but represented a victory for TB vaccine science and community engagement.
Civil society and communities celebrated that the PreVenTB trials represented the largest TB vaccine trial of this century and was funded by high-TB-burden country governments. Further the study was designed to reflect the specific epidemiology of the TB epidemic within India, enrolling populations that stand to benefit the most from a future TB vaccine but were left out of other trials.
Treatment Action Group’s 2026 Tuberculosis Vaccines Pipeline Report surveys major developments in the clinical development of new TB vaccines at this moment of scientific promise and political peril. The pipeline contains 14 candidates and covers vaccines that currently in Phase I, II, or III trials, For each candidate, TAG summarizes the known ongoing, recently completed, or planned clinical trials. Narrative descriptions throughout discuss the notable updates of key candidates that generated the most news over the past year either due to clinical trial results, delays, or the beginning of major new studies.
The WHO has identified the need for three unique types of TB vaccine that extend vaccine coverage to adults and adolescents, improve upon BCG in infants, and provide therapeutic coverage to improve treatment.
Despite the critical need for new vaccines to realize the end of TB, and the need to invest in research and development for new TB vaccines to meet these needs, there is little financial or commercial incentive to invest. Bridging the gap between need and investment requires cross-sectoral partnerships that focus on the entire lifespan of development from discovery to implementation.
Through a global consultative process, EDCTP has developed this roadmap that identifies the key priorities and barriers to TB vaccine R&D and implementation and suggests pathways to overcome them including funding, transparent and open science, and robust stakeholder engagement.
As now-late stage TB vaccine candidates were quietly advancing through the Pipeline, the World Health Organization brought together a group of scientists, developers, funders, civil society, and community representatives to discuss the ideal characteristics of a future TB vaccine. This document presents the preferred characteristics for new TB vaccines, informed by the high need for additional vaccines to meaningfully shift the battle to end TB.
The overarching priorities underscore the need for a vaccine to prevent pulmonary TB and reduce transmission of TB in adults and adolescents alongside a new pediatric vaccine that improves on the safety and efficacy of BCG.



